249 related articles for article (PubMed ID: 11390726)
1. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.
Kosch M; Bahner U; Bettger H; Matzkies F; Teschner M; Schaefer RM
Nephrol Dial Transplant; 2001 Jun; 16(6):1239-44. PubMed ID: 11390726
[TBL] [Abstract][Full Text] [Related]
2. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin.
Stoves J; Inglis H; Newstead CG
Nephrol Dial Transplant; 2001 May; 16(5):967-74. PubMed ID: 11328902
[TBL] [Abstract][Full Text] [Related]
4. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
5. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
6. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
[TBL] [Abstract][Full Text] [Related]
8. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
9. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients.
Chuang CL; Liu RS; Wei YH; Huang TP; Tarng DC
Nephrol Dial Transplant; 2003 Feb; 18(2):370-7. PubMed ID: 12543894
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
12. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
13. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
[TBL] [Abstract][Full Text] [Related]
14. Importance of iron supply for erythropoietin therapy.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
[TBL] [Abstract][Full Text] [Related]
15. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
16. [Current recommendations for the treatment of iron deficiency anemia].
Schaefer RM; Huch R; Krafft A;
Rev Med Suisse; 2007 Apr; 3(105):874-80. PubMed ID: 17514929
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease.
Panesar A; Agarwal R
Am J Kidney Dis; 2002 Nov; 40(5):924-31. PubMed ID: 12407636
[TBL] [Abstract][Full Text] [Related]
18. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Harmankaya O; Eran A
Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
[TBL] [Abstract][Full Text] [Related]
19. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
20. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
